Abstract
The pharmacokinetic profile of pipemidic acid was studied in two groups of young healthy volunteers by using a new, sensitive, high-pressure liquid chromatography procedure for quantitation of pipemidic acid in biological fluids. After oral or intravenous administration, the disposition of pipemidic acid may be described as a one- or a two-compartment open model, respectively. Oral bioavailability was 93.1 +/- 11% (mean +/- standard error). After administration of a 100-mg tablet, 13.4 +/- 2.7% was bound to serum proteins at the time of peak drug concentration in serum. Excretion of pipemidic acid in saliva was negligible, the saliva/serum ratio being about 0.32. At steady state after the twice-daily administration of a 500-mg tablet, which is a recommended dosage regimen, a peak drug concentration in serum of 4.3 +/- 0.5 micrograms/ml was attained in 1.2 +/- 0.1 h. The apparent volume of distribution was 1.9 +/- 0.2 liters/kg, and the elimination half-life was 3.4 +/- 0.2 h. The renal clearance was 4.3 +/- 0.7 ml/min per kg, and the total clearance was 6.3 +/- 0.5 ml/min per kg. Despite a considerable water load, the minimum concentration in urine at the end of a dosing interval averaged 100 micrograms/ml, which widely exceeds the known MIC of pipemidic acid against bacteria commonly causing urinary tract infections.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Archimbaud J. P., Leriche A. Concentration d'acide pipémidique dans le tissu prostatique chez l'homme. Résultats préliminaires. J Urol Nephrol (Paris) 1979 Mar;85(3):191–198. [PubMed] [Google Scholar]
- Brogard J. M., Comte F., Lavillaureix J. Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans. Eur J Drug Metab Pharmacokinet. 1983 Jul-Sep;8(3):251–259. doi: 10.1007/BF03188755. [DOI] [PubMed] [Google Scholar]
- Brühl P., Köhler T., Gundlach G., Krasemann C. Untersuchungen zur Pharmakokinetik der Pipemidsäure bei eingeschränkter Nierenfunktion. Arzneimittelforschung. 1981;31(10):1766–1770. [PubMed] [Google Scholar]
- Galland M. C., Jouve-Bestagne M. H., Rodor F., Jouglard J. Effets indésirables neurologiques des quinolones antibactériens urinaires. Therapie. 1982 Jul-Aug;37(4):481–487. [PubMed] [Google Scholar]
- Graber H., Perényi T., Ludwig E., Arr M. The human biotransformation of nalidixic acid. Int J Clin Pharmacol Biopharm. 1976 Mar;13(2):76–82. [PubMed] [Google Scholar]
- Kurobe N., Nakamura S., Shimizu M. Metabolites of pipemidic acid in human urine. Xenobiotica. 1980 Jan;10(1):37–46. doi: 10.3109/00498258009033729. [DOI] [PubMed] [Google Scholar]
- Meyrier A., Kourilsky O., Montay G., Le Verge R. Utilisation de l'acide pipémidique comme antibiotique chez l'insuffisant rénal. Cinétique des concentrations sériques et urinaires. Pathol Biol (Paris) 1979 Mar;27(3):181–188. [PubMed] [Google Scholar]
- Männistö P. T. Pharmacokinetics of nalidixinic acid and oxolinic acid in healthy women. Clin Pharmacol Ther. 1976 Jan;19(1):37–46. doi: 10.1002/cpt197619137. [DOI] [PubMed] [Google Scholar]
- Männistö P., Solkinen A., Mäntylä R., Gordin A., Salo H., Hänninen U., Niinistö L. Pharmacokinetics of pipemidic acid in healthy middle-aged volunteers and elderly patients with renal insufficiency. Xenobiotica. 1984 Apr;14(4):339–347. doi: 10.3109/00498258409151420. [DOI] [PubMed] [Google Scholar]
- Shimizu M., Nakamura S., Takase Y., Kurobe N. Pipemidic acid: absorption, distribution, and excretion. Antimicrob Agents Chemother. 1975 Apr;7(4):441–446. doi: 10.1128/aac.7.4.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shimizu M., Takase Y., Nakamura S., Katae H., Minami A. Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties. Antimicrob Agents Chemother. 1975 Aug;8(2):132–138. doi: 10.1128/aac.8.2.132. [DOI] [PMC free article] [PubMed] [Google Scholar]